Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens

Michael S. Khodadoust, Niclas Olsson, Lisa E. Wagar, Ole A.W. Haabeth, Binbin Chen, Kavya Swaminathan, Keith Rawson, Chih Long Liu, David Steiner, Peder Lund, Samhita Rao, Lichao Zhang, Caleb Marceau, Henning Stehr, Aaron M. Newman, Debra K. Czerwinski, Victoria E.H. Carlton, Martin Moorhead, Malek Faham, Holbrook E. KohrtJan Carette, Michael R. Green, Mark M. Davis, Ronald Levy, Joshua E. Elias, Ash A. Alizadeh

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Cancer somatic mutations can generate neoantigens that distinguish malignant from normal cells. However, the personalized identification and validation of neoantigens remains a major challenge. Here we discover neoantigens in human mantle-cell lymphomas by using an integrated genomic and proteomic strategy that interrogates tumour antigen peptides presented by major histocompatibility complex (MHC) class I and class II molecules. We applied this approach to systematically characterize MHC ligands from 17 patients. Remarkably, all discovered neoantigenic peptides were exclusively derived from the lymphoma immunoglobulin heavy- or light-chain variable regions. Although we identified MHC presentation of private polymorphic germline alleles, no mutated peptides were recovered from non-immunoglobulin somatically mutated genes. Somatic mutations within the immunoglobulin variable region were almost exclusively presented by MHC class II. We isolated circulating CD4 + T cells specific for immunoglobulin-derived neoantigens and found these cells could mediate killing of autologous lymphoma cells. These results demonstrate that an integrative approach combining MHC isolation, peptide identification, and exome sequencing is an effective platform to uncover tumour neoantigens. Application of this strategy to human lymphoma implicates immunoglobulin neoantigens as targets for lymphoma immunotherapy.

Original languageEnglish (US)
Pages (from-to)723-727
Number of pages5
JournalNature
Volume543
Issue number7647
DOIs
StatePublished - Mar 30 2017

Fingerprint

Antigen Presentation
Major Histocompatibility Complex
Immunoglobulins
Lymphoma
Peptides
Immunoglobulin Variable Region
Exome
Mantle-Cell Lymphoma
Mutation
Neoplasm Antigens
Proteomics
Immunotherapy
Neoplasms
Alleles
Ligands
T-Lymphocytes
Light
Genes

ASJC Scopus subject areas

  • General

Cite this

Khodadoust, M. S., Olsson, N., Wagar, L. E., Haabeth, O. A. W., Chen, B., Swaminathan, K., ... Alizadeh, A. A. (2017). Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature, 543(7647), 723-727. https://doi.org/10.1038/nature21433

Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. / Khodadoust, Michael S.; Olsson, Niclas; Wagar, Lisa E.; Haabeth, Ole A.W.; Chen, Binbin; Swaminathan, Kavya; Rawson, Keith; Liu, Chih Long; Steiner, David; Lund, Peder; Rao, Samhita; Zhang, Lichao; Marceau, Caleb; Stehr, Henning; Newman, Aaron M.; Czerwinski, Debra K.; Carlton, Victoria E.H.; Moorhead, Martin; Faham, Malek; Kohrt, Holbrook E.; Carette, Jan; Green, Michael R.; Davis, Mark M.; Levy, Ronald; Elias, Joshua E.; Alizadeh, Ash A.

In: Nature, Vol. 543, No. 7647, 30.03.2017, p. 723-727.

Research output: Contribution to journalArticle

Khodadoust, MS, Olsson, N, Wagar, LE, Haabeth, OAW, Chen, B, Swaminathan, K, Rawson, K, Liu, CL, Steiner, D, Lund, P, Rao, S, Zhang, L, Marceau, C, Stehr, H, Newman, AM, Czerwinski, DK, Carlton, VEH, Moorhead, M, Faham, M, Kohrt, HE, Carette, J, Green, MR, Davis, MM, Levy, R, Elias, JE & Alizadeh, AA 2017, 'Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens', Nature, vol. 543, no. 7647, pp. 723-727. https://doi.org/10.1038/nature21433
Khodadoust MS, Olsson N, Wagar LE, Haabeth OAW, Chen B, Swaminathan K et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature. 2017 Mar 30;543(7647):723-727. https://doi.org/10.1038/nature21433
Khodadoust, Michael S. ; Olsson, Niclas ; Wagar, Lisa E. ; Haabeth, Ole A.W. ; Chen, Binbin ; Swaminathan, Kavya ; Rawson, Keith ; Liu, Chih Long ; Steiner, David ; Lund, Peder ; Rao, Samhita ; Zhang, Lichao ; Marceau, Caleb ; Stehr, Henning ; Newman, Aaron M. ; Czerwinski, Debra K. ; Carlton, Victoria E.H. ; Moorhead, Martin ; Faham, Malek ; Kohrt, Holbrook E. ; Carette, Jan ; Green, Michael R. ; Davis, Mark M. ; Levy, Ronald ; Elias, Joshua E. ; Alizadeh, Ash A. / Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. In: Nature. 2017 ; Vol. 543, No. 7647. pp. 723-727.
@article{f83bd79977b6458a9017fea13f49c91a,
title = "Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens",
abstract = "Cancer somatic mutations can generate neoantigens that distinguish malignant from normal cells. However, the personalized identification and validation of neoantigens remains a major challenge. Here we discover neoantigens in human mantle-cell lymphomas by using an integrated genomic and proteomic strategy that interrogates tumour antigen peptides presented by major histocompatibility complex (MHC) class I and class II molecules. We applied this approach to systematically characterize MHC ligands from 17 patients. Remarkably, all discovered neoantigenic peptides were exclusively derived from the lymphoma immunoglobulin heavy- or light-chain variable regions. Although we identified MHC presentation of private polymorphic germline alleles, no mutated peptides were recovered from non-immunoglobulin somatically mutated genes. Somatic mutations within the immunoglobulin variable region were almost exclusively presented by MHC class II. We isolated circulating CD4 + T cells specific for immunoglobulin-derived neoantigens and found these cells could mediate killing of autologous lymphoma cells. These results demonstrate that an integrative approach combining MHC isolation, peptide identification, and exome sequencing is an effective platform to uncover tumour neoantigens. Application of this strategy to human lymphoma implicates immunoglobulin neoantigens as targets for lymphoma immunotherapy.",
author = "Khodadoust, {Michael S.} and Niclas Olsson and Wagar, {Lisa E.} and Haabeth, {Ole A.W.} and Binbin Chen and Kavya Swaminathan and Keith Rawson and Liu, {Chih Long} and David Steiner and Peder Lund and Samhita Rao and Lichao Zhang and Caleb Marceau and Henning Stehr and Newman, {Aaron M.} and Czerwinski, {Debra K.} and Carlton, {Victoria E.H.} and Martin Moorhead and Malek Faham and Kohrt, {Holbrook E.} and Jan Carette and Green, {Michael R.} and Davis, {Mark M.} and Ronald Levy and Elias, {Joshua E.} and Alizadeh, {Ash A.}",
year = "2017",
month = "3",
day = "30",
doi = "10.1038/nature21433",
language = "English (US)",
volume = "543",
pages = "723--727",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7647",

}

TY - JOUR

T1 - Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens

AU - Khodadoust, Michael S.

AU - Olsson, Niclas

AU - Wagar, Lisa E.

AU - Haabeth, Ole A.W.

AU - Chen, Binbin

AU - Swaminathan, Kavya

AU - Rawson, Keith

AU - Liu, Chih Long

AU - Steiner, David

AU - Lund, Peder

AU - Rao, Samhita

AU - Zhang, Lichao

AU - Marceau, Caleb

AU - Stehr, Henning

AU - Newman, Aaron M.

AU - Czerwinski, Debra K.

AU - Carlton, Victoria E.H.

AU - Moorhead, Martin

AU - Faham, Malek

AU - Kohrt, Holbrook E.

AU - Carette, Jan

AU - Green, Michael R.

AU - Davis, Mark M.

AU - Levy, Ronald

AU - Elias, Joshua E.

AU - Alizadeh, Ash A.

PY - 2017/3/30

Y1 - 2017/3/30

N2 - Cancer somatic mutations can generate neoantigens that distinguish malignant from normal cells. However, the personalized identification and validation of neoantigens remains a major challenge. Here we discover neoantigens in human mantle-cell lymphomas by using an integrated genomic and proteomic strategy that interrogates tumour antigen peptides presented by major histocompatibility complex (MHC) class I and class II molecules. We applied this approach to systematically characterize MHC ligands from 17 patients. Remarkably, all discovered neoantigenic peptides were exclusively derived from the lymphoma immunoglobulin heavy- or light-chain variable regions. Although we identified MHC presentation of private polymorphic germline alleles, no mutated peptides were recovered from non-immunoglobulin somatically mutated genes. Somatic mutations within the immunoglobulin variable region were almost exclusively presented by MHC class II. We isolated circulating CD4 + T cells specific for immunoglobulin-derived neoantigens and found these cells could mediate killing of autologous lymphoma cells. These results demonstrate that an integrative approach combining MHC isolation, peptide identification, and exome sequencing is an effective platform to uncover tumour neoantigens. Application of this strategy to human lymphoma implicates immunoglobulin neoantigens as targets for lymphoma immunotherapy.

AB - Cancer somatic mutations can generate neoantigens that distinguish malignant from normal cells. However, the personalized identification and validation of neoantigens remains a major challenge. Here we discover neoantigens in human mantle-cell lymphomas by using an integrated genomic and proteomic strategy that interrogates tumour antigen peptides presented by major histocompatibility complex (MHC) class I and class II molecules. We applied this approach to systematically characterize MHC ligands from 17 patients. Remarkably, all discovered neoantigenic peptides were exclusively derived from the lymphoma immunoglobulin heavy- or light-chain variable regions. Although we identified MHC presentation of private polymorphic germline alleles, no mutated peptides were recovered from non-immunoglobulin somatically mutated genes. Somatic mutations within the immunoglobulin variable region were almost exclusively presented by MHC class II. We isolated circulating CD4 + T cells specific for immunoglobulin-derived neoantigens and found these cells could mediate killing of autologous lymphoma cells. These results demonstrate that an integrative approach combining MHC isolation, peptide identification, and exome sequencing is an effective platform to uncover tumour neoantigens. Application of this strategy to human lymphoma implicates immunoglobulin neoantigens as targets for lymphoma immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85018926405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018926405&partnerID=8YFLogxK

U2 - 10.1038/nature21433

DO - 10.1038/nature21433

M3 - Article

C2 - 28329770

AN - SCOPUS:85018926405

VL - 543

SP - 723

EP - 727

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7647

ER -